Classes
DEA Class; Rx
Common Brand Names; Patanase, Pataday, Patanol, Pazeo
- Allergy, Intranasal;
- Antihistamines, Intranasal
Description
Ophthamic and nasal antihistamine (H1-blocker) and mast cell stabilizer
Ophthalmic solution for prevention of ocular pruritus due to allergic conjunctivitis
Nasal spray for seasonal allergic rhinitis
Indications
Indicated for the treatment of the signs and symptoms of allergic conjunctivitis, including ocular pruritus.
Contraindications
Hypersensitivity
Adverse Effects
- Bitter taste (12.8%; 1% pediatric)
- Respiratory epistaxis (3-25%)
- Headache (4.4%)
- Depression (2%)
- Fatigue (1%)
- Somnolence (1%)
- Weight gain (1%)
- Epistaxis (3.2%; 5.7% pediatric)
- Upper respiratory tract infection (2.6% pediatric)
- Pharyngolaryngeal pain (2.2%)
- Postnasal drip (1.5%)
- Cough (1.4%)
- Urinary tract infection (1.2%)
- Upper respiratory tract infection in children (3%)
Warnings
May cause epistaxis, nasal ulceration, or nasal septal perforation
Avoid with nasal disease other than allergic rhinitis
May impair mental/physical abilities required for hazardous tasks (eg, driving, operating machinery)
Avoid concurrent use of alcohol or other CNS depressants (possible additive sedation)
Pregnancy and Lactation
Published data from postmarketing experience with antihistamines, have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production; although orally administered drug is present in rat milk, there is no information about nasally administered drug
Maximum Dosage
2 drops/day 0.1% ophthalmic solution in each affected eye; 1 drop/day 0.2% or 0.7% ophthalmic solution in each affected eye; 4 nasal sprays/day in each nostril.
2 drops/day 0.1% ophthalmic solution in each affected eye; 1 drop/day 0.2% or 0.7% ophthalmic solution in each affected eye; 4 nasal sprays/day in each nostril.
2 drops/day 0.1% ophthalmic solution each affected eye; 1 drop/day 0.2% or 0.7% ophthalmic solution in each affected eye; 4 nasal sprays/day in each nostril.
12 years: 2 drops/day 0.1% ophthalmic solution each affected eye; 1 drop/day 0.2% or 0.7% ophthalmic solution in each affected eye; 4 nasal sprays/day in each nostril.
6 to 11 years: 2 drops/day 0.1% ophthalmic solution each affected eye; 1 drop/day 0.2% or 0.7% ophthalmic solution in each affected eye; 2 nasal sprays/day in each nostril.
2 to 5 years: 2 drops/day 0.1% ophthalmic solution in each affected eye; 1 drop/day 0.2% or 0.7% ophthalmic solution in each affected eye. Safety and efficacy have not been established for the nasal spray; however, 2 nasal sprays/day in each nostril has been studied.
younger than 2 years: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Olopatadine hydrochloride
nasal spray
- 6% (665mcg/100 microliters spray)
ophthalmic solution
- 0.1% (Patanol [OTC])
- 0.2% (Pataday [OTC])
- 0.7% (Pazeo)
